March 10, 2025 – Novo Nordisk’s hopes for a next-generation weight loss drug have hit a setback. The company’s experimental treatment, CagriSema, has once again delivered modest weight loss results, failing to clearly outperform Eli Lilly’s rival treatment, Zepbound.
Key Findings from the Latest Trial
- In a 68-week study, people with obesity and diabetes taking CagriSema lost an average of 14% of their body weight.
- This was 11 percentage points more than those on a placebo but fell short of expectations.
- The results follow another underwhelming trial in non-diabetic patients in December 2024.
Why It Matters
Novo Nordisk has dominated the weight loss market with Wegovy, which generated $8.4 billion in sales in 2024. However, the company now faces stiff competition from Eli Lilly’s Zepbound, which has demonstrated greater weight loss and is gaining stronger insurance coverage.
Novo had positioned CagriSema as a potential game-changer, combining semaglutide (the key ingredient in Wegovy) with cagrilintide, an additional weight-loss agent. The goal was to outperform Zepbound—but so far, the data suggests only a modest improvement over Wegovy rather than a significant leap forward.
Investor and Market Reaction
- Following the announcement, Novo Nordisk’s stock dropped nearly 10%, continuing a downward trend driven by competition concerns.
- Analysts had hoped CagriSema would deliver 25% weight loss in non-diabetic patients—a benchmark it missed in an earlier trial.
- Manufacturing challenges also add potential hurdles: unlike Zepbound, CagriSema requires a dual-chambered injection pen, complicating production and delivery.
What’s Next for Novo Nordisk?
- The company has already planned a new Phase 3 trial to explore whether higher doses of CagriSema could lead to stronger results.
- Analysts now question whether Zepbound’s mechanism (GLP-1 + GIP stimulation) is simply more effective than Novo’s dual-drug approach.
- This could create opportunities for rival drug developers like Amgen, Roche, and Viking Therapeutics, who are working on similar hormone-targeting weight-loss treatments.
The Bottom Line
While CagriSema still shows some promise, it has not yet delivered the breakthrough Novo Nordisk needed to maintain its dominance. With Zepbound gaining momentum, Novo now faces an uphill battle to stay competitive in the weight loss drug market.
For further updates, visit www.novonordisk.com.